Replies to post #209734 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Long, I agree that starting the clock early makes the difference in median stand out less. I even posed that long ago. But the P value is unchanged by adding a constant time offset.

In their final analysis, Optune treatment median OS was cited at 19.6 months, whereas DCVax blended OS is cited on both JTM and SNO figures as 23.1 months. Advantage DCVax. Until you subtract the 3.1 months which was the DCVax median time from surgery to randomization, and you get 19.6 v 20.0 months.

Why not add the 3.8 months to the Optune MOS instead? Now one has Optune at 23.4 months vs DCVax (blended) at 23.1 months.

And why add/subtract the median time from surgery when you should be using the mean unless you have raw data? If you look at the Stupp trial as an example for time between surgery and adjuvant, you will see that a decent number of patients take far more than the nominal 3 months to begin adjvant treatment. I would gladly bet you that the blended median in DCVax-L from randomization is less than 20.0 months due to this effect.

Way to many ways to play with such non data.

[flipper44]

Only 24 months after last patient enrolled in Optune trial. (Their last update)

Only 10.3 % alive in the blended population. (In the DCVax-L trial, approximately over two and-a-half times that number of patients were alive at a similar time in its trial.)

Here was the last Optune update of patients still alive at 24 months after last patient enrolled.